Organon & Co.
Every calculator, already run for OGN
Open the full toolkit →You have the numbers on OGN. Get the argument.
A written report on which of these readings actually decide the outcome for Organon & Co., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering OGNAnalyst Price Target Disagreement for Organon & Co.
Wall Street's bull case implies +3% from the current price; the bear case implies -41%. A 44% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for OGN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine…
OGN — frequently asked
Is OGN a buy right now?
Wall Street's consensus rating on Organon & Co. is none across 5 analysts, with a mean price target of $11.25 (-18% vs. the current $13.64). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is OGN overvalued?
OGN trades at 17.5x trailing earnings, against a DCF fair value of $67 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is OGN's next earnings date?
Organon & Co. is next scheduled to report earnings around Nov 9, 2026. A full OGN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Organon & Co.?
Analysts covering Organon & Co. (OGN) range from a bear-case target of $8.00 to a bull-case high of $14.00, with a mean consensus target of $11.25 across 4 analysts. The spread of $6.00 (44% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Organon & Co. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Organon & Co.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full OGN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Organon & Co., in minutes. 3 free reports included with every account — no credit card required.